{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:28:17Z","timestamp":1787110097862,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020371","name":"New Sunshine Charity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105470","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:38:44Z","timestamp":1782923924000},"page":"105470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation"],"prefix":"10.1016","volume":"225","author":[{"given":"Xiao-Lei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Ni","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105470_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113797","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105470_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112038","article-title":"Marine peptides in breast cancer: Therapeutic and mechanistic understanding","volume":"142","author":"Ahmed","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105470_bib3","doi-asserted-by":"crossref","first-page":"18931","DOI":"10.1002\/cam4.6508","article-title":"Alternative promoters and splicing create multiple functionally distinct isoforms of oestrogen receptor alpha in breast cancer and healthy tissues","volume":"12","author":"Balcazar Lopez","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105470_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fonc.2016.00145","article-title":"Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance","volume":"6","author":"Bellerby","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105470_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phrs.2019.03.008","article-title":"Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration","volume":"143","author":"Buoso","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"5-6","key":"10.1016\/j.critrevonc.2026.105470_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000510124","article-title":"Molecular origin, expression regulation, and biological function of androgen receptor splicing variant 7 in prostate cancer","volume":"105","author":"Chen","year":"2021","journal-title":"Urol. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12935-023-03094-3","article-title":"The role of alternative pre-mRNA splicing in cancer progression","volume":"23","author":"Choi","year":"2023","journal-title":"Cancer Cell. Int."},{"issue":"Pt 1","key":"10.1016\/j.critrevonc.2026.105470_bib8","article-title":"Alternative pre-mRNA splicing in stem cell function and therapeutic potential: A critical review of current evidence","volume":"268","author":"Cui","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.critrevonc.2026.105470_bib9","doi-asserted-by":"crossref","unstructured":"Demir Cetinkaya, B., Biray Avci, C., 2022. Molecular perspective on targeted therapy in breast cancer: a review of current status. Medical oncology (Northwood, London, England) 39(10), 149.","DOI":"10.1007\/s12032-022-01749-1"},{"key":"10.1016\/j.critrevonc.2026.105470_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216124","article-title":"MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression","volume":"560","author":"Deng","year":"2023","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105470_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj4009","article-title":"SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1","volume":"10","author":"Deng","year":"2024","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib12","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1007\/s00262-023-03543-y","article-title":"An alternatively spliced PD-L1 isoform PD-L1\u22063, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response","volume":"72","author":"Dioken","year":"2023","journal-title":"Cancer immunology immunotherapy CII"},{"key":"10.1016\/j.critrevonc.2026.105470_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110128","article-title":"LncRNA ZNF649-AS1 promotes trastuzumab resistance and TAM-dependent PD-L1 expression in breast cancer by regulating EXOC7 alternative splicing","volume":"761","author":"Dong","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105470_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06507-x","article-title":"Modification of BCLX pre-mRNA splicing has antitumor efficacy alone or in combination with radiotherapy in human glioblastoma cells","volume":"15","author":"Dou","year":"2024","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13046-021-02001-w","article-title":"Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation","volume":"40","author":"Dou","year":"2021","journal-title":"J Exp Clin. Cancer Res."},{"issue":"47","key":"10.1016\/j.critrevonc.2026.105470_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202404609","article-title":"m(6)A-modified SNRPA controls alternative splicing of ERCC1 Exon 8 to induce cisplatin resistance in lung adenocarcinoma","volume":"11","author":"Fan","year":"2024","journal-title":"Advanced science"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105470_bib17","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846078","article-title":"Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways","volume":"20","author":"G\u00f6kmen-Polar","year":"2019","journal-title":"EMBO Rep."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105470_bib18","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1158\/1078-0432.CCR-17-2259","article-title":"BQ323636.1, a Novel Splice Variant to NCOR2, as a predictor for tamoxifen-resistant breast cancer","volume":"24","author":"Gong","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105470_bib19","first-page":"1942","article-title":"Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer","volume":"35","author":"Guardia","year":"2025","journal-title":"Genome Res."},{"key":"10.1016\/j.critrevonc.2026.105470_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1190479","article-title":"Aberrant PI3K\u03b4 splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers","volume":"14","author":"Ha","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105470_bib21","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.18632\/oncotarget.27789","article-title":"HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes","volume":"11","author":"Hart","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105470_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2024.108513","article-title":"Mechanistic insights into cisplatin response in breast tumors: Molecular determinants and drug\/nanotechnology-based therapeutic opportunities","volume":"794","author":"Hashemi","year":"2024","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00018-024-05515-6","article-title":"The splicing machinery is dysregulated and represents a therapeutic vulnerability in breast cancer","volume":"82","author":"Herm\u00e1n-S\u00e1nchez","year":"2024","journal-title":"Cell. Mol. life Sci. CMLS"},{"key":"10.1016\/j.critrevonc.2026.105470_bib24","doi-asserted-by":"crossref","unstructured":"Hull, R., Gaudji, B., Bates, D.O., 2024. Unraveling the impact of aberrant splicing machinery on drug resistance in breast cancer: identifying targets for innovative counteractive strategiesOvercoming Breast Cancer Therapy Resistance Mechanisms Precision AI-Powered Approaches157185.","DOI":"10.1007\/978-3-031-52860-6_7"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105470_bib25","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.34067\/KID.0000000566","article-title":"Acute kidney injury associated with anticancer therapies: small molecules and targeted therapies","volume":"5","author":"Kala","year":"2024","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55460-9","article-title":"Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis","volume":"9","author":"Kedashiro","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105470_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104351","article-title":"Recent strategies to overcome breast cancer resistance","volume":"197","author":"Khan","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/genes10010041","article-title":"Survivin splice variants in arsenic trioxide (As\u2082O\u2083)-induced deactivation of PI3K and MAPK Cell signalling pathways in MCF-7 Cells","volume":"10","author":"Laka","year":"2019","journal-title":"Genes"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105470_bib29","doi-asserted-by":"crossref","first-page":"11239","DOI":"10.1093\/nar\/gkad772","article-title":"Alternative splicing of BCL-x is controlled by RBM25 binding to a G-quadruplex in BCL-x pre-mRNA","volume":"51","author":"Le S\u00e9n\u00e9chal","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105470_bib30","doi-asserted-by":"crossref","first-page":"12768","DOI":"10.1093\/nar\/gkac1130","article-title":"The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress","volume":"50","author":"Lemaitre","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105470_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030533","article-title":"A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2","volume":"12","author":"Leung","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105470_bib32","article-title":"Cyperotundone promotes chemosensitivity of breast cancer via SRSF1","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib33","first-page":"71","article-title":"Expression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity","volume":"9","author":"Li","year":"2022","journal-title":"Mil. Med. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biom12121834","article-title":"Comprehensive analysis of transcriptomics and genetic alterations identifies potential mechanisms underlying anthracycline therapy resistance in breast cancer","volume":"12","author":"Liu","year":"2022","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105470_bib35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/1535-7163.MCT-17-0026","article-title":"TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105470_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/genes12071085","article-title":"Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy","volume":"12","author":"Mehterov","year":"2021","journal-title":"Genes"},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105470_bib37","doi-asserted-by":"crossref","first-page":"40692","DOI":"10.18632\/oncotarget.5827","article-title":"A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1\/XBP1","volume":"6","author":"Ming","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13100-025-00341-4","article-title":"Alternative splicing of transposable elements in human breast cancer","volume":"16","author":"Nesta","year":"2025","journal-title":"Mob. DNA"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib39","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mc.22248","article-title":"Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair","volume":"54","author":"Oji","year":"2015","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib40","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049233","article-title":"Alternative RNA splicing in tumour heterogeneity, plasticity and therapy","volume":"15","author":"\u00d6ther-Gee Pohl","year":"2022","journal-title":"Dis. Models & Mech."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105470_bib41","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41418-024-01294-6","article-title":"The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer","volume":"31","author":"Pai","year":"2024","journal-title":"Cell. death Differ."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib42","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1158\/2767-9764.CRC-23-0309","article-title":"SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors","volume":"4","author":"Palmer","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2022.119346","article-title":"Resistance to CDK4\/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer","volume":"1869","author":"Papadimitriou","year":"2022","journal-title":"Biochim. Et. Biophys. Acta Mol. Cell. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105470_bib44","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/s12276-025-01578-y","article-title":"RPS24 microexon isoform as a novel biomarker for estrogen receptor-positive breast cancer progression and therapeutic resistance","volume":"57","author":"Park","year":"2025","journal-title":"Exp. & Mol. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105470_bib45","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41416-024-02853-x","article-title":"SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer","volume":"131","author":"Phillips","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105470_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101644","article-title":"CD44 occurring alternative splicing promotes cisplatin resistance and evokes tumor immune response in oral squamous cell carcinoma cells","volume":"31","author":"Qiao","year":"2023","journal-title":"Transl. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105470_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216198","article-title":"Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches","volume":"24","author":"Raheem","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105470_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1612461","article-title":"GPATCH3, a splicing regulator that facilitates tumor immune evasion via the modulation of ATPase activity of DHX15","volume":"16","author":"Ren","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105470_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib50","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105470_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41419-023-06031-4","article-title":"p53 isoform expression promotes a stemness phenotype and inhibits doxorubicin sensitivity in breast cancer","volume":"14","author":"Steffens Reinhardt","year":"2023","journal-title":"Cell. death & Dis."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105470_bib52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41419-022-05349-9","article-title":"Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage","volume":"13","author":"Steffens Reinhardt","year":"2022","journal-title":"Cell. death & Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s10020-024-00849-0","article-title":"Downregulation of HNRNPA1 induced neoantigen generation via regulating alternative splicing","volume":"30","author":"Sun","year":"2024","journal-title":"Mol. Med. (Camb. Mass. )"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105470_bib54","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1097\/CM9.0000000000003278","article-title":"Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022","volume":"137","author":"Sun","year":"2024","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105470_bib55","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/nar\/gkz1213","article-title":"ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin","volume":"48","author":"Tanaka","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105470_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112637","article-title":"Dual Epigenetic Regulation of ER\u03b136 Expression in Breast Cancer Cells","volume":"20","author":"Thiebaut","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105470_bib57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/CBM-200858","article-title":"Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer","volume":"32","author":"Topno","year":"2021","journal-title":"Cancer Biomark."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105470_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26114989","article-title":"The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer","volume":"26","author":"Tsoi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib59","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1080\/15476286.2018.1551692","article-title":"Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells","volume":"15","author":"Tyson-Capper","year":"2018","journal-title":"RNA Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib60","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1007\/s00262-023-03534-z","volume":"72","author":"Wahid","year":"2023","journal-title":"Cancer immunology immunotherapy CII"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41523-025-00830-y","article-title":"CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial","volume":"11","author":"Wahner Hendrickson","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105470_bib62","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105470_bib63","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1-\u039411q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105470_bib64","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1158\/0008-5472.CAN-07-3170","article-title":"Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists","volume":"68","author":"Wang","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib65","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1038\/s41467-024-53561-2","article-title":"A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105470_bib66","first-page":"2349","article-title":"Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin","volume":"47","author":"Wang","year":"2024","journal-title":"Cell. Oncol. (Dordr. Neth. )"},{"key":"10.1016\/j.critrevonc.2026.105470_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103382","article-title":"FMRP protects breast cancer cells from ferroptosis by promoting SLC7A11 alternative splicing through interacting with hnRNPM","volume":"77","author":"Wang","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2026.105470_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102896","article-title":"The novel \u03b2-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer","volume":"67","author":"Wang","year":"2023","journal-title":"Redox Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105470_bib69","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jcmm.17716","article-title":"Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4\/CyclinD1-pRB-E2F1 pathway","volume":"27","author":"Wang","year":"2023","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib70","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s42003-020-0983-4","article-title":"SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells","volume":"3","author":"Wang","year":"2020","journal-title":"Commun. Biol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105470_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf1171","article-title":"Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response","volume":"53","author":"Xiong","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40164-022-00361-3","article-title":"Increased expression of ECT2 predicts the poor prognosis of breast cancer patients","volume":"11","author":"Yi","year":"2022","journal-title":"Exp. Hematol. & Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108070","article-title":"Downregulation of the splicing regulator NSRP1 confers resistance to CDK4\/6 inhibitors via activation of interferon signaling in breast cancer","volume":"301","author":"Yu","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105470_bib74","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41388-024-03134-w","article-title":"Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer","volume":"43","author":"Yu","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41419-025-07710-0","article-title":"A novel taxane SB-T-101141 triggers a noncanonical ferroptosis to overcome Paclitaxel resistance of breast cancer via iron homeostasis-related KHSRP","volume":"16","author":"Zhang","year":"2025","journal-title":"Cell. death & Dis."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105470_bib76","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/cmdc.202000642","article-title":"A comprehensive overview of structure-activity relationships of small-molecule splicing modulators targeting SF3B1 as anticancer agents","volume":"15","author":"Zhang","year":"2020","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib77","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105470_bib78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.18632\/oncotarget.26530","article-title":"FGFR1\u03b2 is a driver isoform of FGFR1 alternative splicing in breast cancer cells","volume":"10","author":"Zhao","year":"2019","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105470_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70545","article-title":"Alternative splicing: molecular mechanisms, biological functions, diseases, and potential therapeutic targets","volume":"6","author":"Zhu","year":"2025","journal-title":"MedComm"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:52:18Z","timestamp":1787107938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":79,"alternative-id":["S1040842826003574"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105470","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105470"}}